The ideal fibrinolytic: can drug design improve clinical results?
Van de Werf
F J
FJ
Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium.
D015195:Drug Design; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D008666:Metalloendopeptidases / Q000737:chemistry / Q000627:therapeutic use; D015394:Molecular Structure; D009203:Myocardial Infarction / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D000077785:Tenecteplase; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000737:chemistry / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C081981:lanoteplase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus; C067551:saruplase; D000077785:Tenecteplase